DFDA

Cetuximab (Targeted Therapy)

Treatment for Larynx Cancer

Typical Dosage: 400 mg/m2 loading dose, then 250 mg/m2 weekly

Effectiveness
65%
Safety Score
45%
Clinical Trials
3
Participants
20K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
400 mg/m2 loading dose, then 250 mg/m2 weekly
Time to Effect
Weeks
Treatment Duration
Weekly for 7 weeks (with radiation)
Evidence Quality
MODERATE
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30,000
Monitoring:$5,000
Side Effect Mgmt:$4,000
Total Annual:$39,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$200,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$97,500
Cost per Remission
$195,000
Cetuximab (Targeted Therapy) Outcomes

for Larynx Cancer

Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+40%
Remission Rate
+20%
Common Side Effects
Acne-like rash
+80%
Hypomagnesemia
+50%
Infusion reactions
+20%
Diarrhea
+25%
Fatigue
+40%

Sources:

civilica.com
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
2 active trials recruiting for Cetuximab (Targeted Therapy) in Larynx Cancer

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

NCT06706401RECRUITINGPHASE3
View Study
460 participants
INTERVENTIONAL
Angers, France +6 more
Started: Feb 20, 2025

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

NCT03082534ACTIVE NOT RECRUITINGPHASE2
View Study
78 participants
INTERVENTIONAL
La Jolla, United States +3 more
Started: Mar 28, 2017